111 related articles for article (PubMed ID: 17487395)
1. Biphasic expression of RhoGDI2 in the progression of breast cancer and its negative relation with lymph node metastasis.
Hu LD; Zou HF; Zhan SX; Cao KM
Oncol Rep; 2007 Jun; 17(6):1383-9. PubMed ID: 17487395
[TBL] [Abstract][Full Text] [Related]
2. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia.
Wu Y; McRoberts K; Berr SS; Frierson HF; Conaway M; Theodorescu D
Oncogene; 2007 Feb; 26(5):765-73. PubMed ID: 16878152
[TBL] [Abstract][Full Text] [Related]
3. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer.
Theodorescu D; Sapinoso LM; Conaway MR; Oxford G; Hampton GM; Frierson HF
Clin Cancer Res; 2004 Jun; 10(11):3800-6. PubMed ID: 15173088
[TBL] [Abstract][Full Text] [Related]
4. RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer.
Cho HJ; Baek KE; Park SM; Kim IK; Choi YL; Cho HJ; Nam IK; Hwang EM; Park JY; Han JY; Kang SS; Kim DC; Lee WS; Lee MN; Oh GT; Kim JW; Lee CW; Yoo J
Clin Cancer Res; 2009 Apr; 15(8):2612-9. PubMed ID: 19351766
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of RhoGDI2 correlates with tumor progression and poor prognosis in colorectal carcinoma.
Li X; Wang J; Zhang X; Zeng Y; Liang L; Ding Y
Ann Surg Oncol; 2012 Jan; 19(1):145-53. PubMed ID: 21861235
[TBL] [Abstract][Full Text] [Related]
6. RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression.
Cho HJ; Baek KE; Park SM; Kim IK; Nam IK; Choi YL; Park SH; Im MJ; Choi J; Ryu J; Kim JW; Lee CW; Kang SS; Yoo J
Cancer Lett; 2011 Dec; 311(1):48-56. PubMed ID: 21752536
[TBL] [Abstract][Full Text] [Related]
7. PLCγ is required for RhoGDI2-mediated cisplatin resistance in gastric cancer.
Cho HJ; Baek KE; Nam IK; Park SM; Kim IK; Park SH; Im MJ; Ryu KJ; Yoo JM; Hong SC; Kim JW; Lee CW; Yoo J
Biochem Biophys Res Commun; 2011 Oct; 414(3):575-80. PubMed ID: 21986528
[TBL] [Abstract][Full Text] [Related]
8. RhoGDI2 as a therapeutic target in cancer.
Cho HJ; Baek KE; Yoo J
Expert Opin Ther Targets; 2010 Jan; 14(1):67-75. PubMed ID: 20001211
[TBL] [Abstract][Full Text] [Related]
9. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2.
Titus B; Frierson HF; Conaway M; Ching K; Guise T; Chirgwin J; Hampton G; Theodorescu D
Cancer Res; 2005 Aug; 65(16):7320-7. PubMed ID: 16103083
[TBL] [Abstract][Full Text] [Related]
10. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer.
Gildea JJ; Seraj MJ; Oxford G; Harding MA; Hampton GM; Moskaluk CA; Frierson HF; Conaway MR; Theodorescu D
Cancer Res; 2002 Nov; 62(22):6418-23. PubMed ID: 12438227
[TBL] [Abstract][Full Text] [Related]
11. RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation.
Harding MA; Theodorescu D
Urol Oncol; 2007; 25(5):401-6. PubMed ID: 17826660
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of HRad17 mRNA in human breast cancer: correlation with lymph node metastasis.
Kataoka A; Sadanaga N; Mimori K; Ueo H; Barnard GF; Sugimachi K; Auclair D; Chen LB; Mori M
Clin Cancer Res; 2001 Sep; 7(9):2815-20. PubMed ID: 11555598
[TBL] [Abstract][Full Text] [Related]
13. Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.
Zhang Z; Yamashita H; Toyama T; Yamamoto Y; Kawasoe T; Iwase H
Clin Cancer Res; 2006 Nov; 12(21):6410-4. PubMed ID: 17085653
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis.
Nakamura Y; Yasuoka H; Tsujimoto M; Yoshidome K; Nakahara M; Nakao K; Nakamura M; Kakudo K
Clin Cancer Res; 2006 Feb; 12(4):1201-7. PubMed ID: 16489074
[TBL] [Abstract][Full Text] [Related]
15. RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis.
Oh JJ; Taschereau EO; Koegel AK; Ginther CL; Rotow JK; Isfahani KZ; Slamon DJ
Lung Cancer; 2010 Dec; 70(3):253-62. PubMed ID: 20338664
[TBL] [Abstract][Full Text] [Related]
16. Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function.
Wu Y; Moissoglu K; Wang H; Wang X; Frierson HF; Schwartz MA; Theodorescu D
Proc Natl Acad Sci U S A; 2009 Apr; 106(14):5807-12. PubMed ID: 19321744
[TBL] [Abstract][Full Text] [Related]
17. [Identification of the differentially expressed genes between primary breast cancer and paired lymph node metastasis through combining mRNA differential display and gene microarray].
Feng YM; Gao G; Zhang F; Chen H; Wan YF; Li XQ
Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(39):2749-55. PubMed ID: 17199993
[TBL] [Abstract][Full Text] [Related]
18. ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer.
Zhang Z; Yamashita H; Toyama T; Sugiura H; Ando Y; Mita K; Hamaguchi M; Kawaguchi M; Miura Y; Iwase H
Clin Cancer Res; 2005 Jan; 11(1):193-8. PubMed ID: 15671546
[TBL] [Abstract][Full Text] [Related]
19. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
[TBL] [Abstract][Full Text] [Related]
20. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
